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a b s t r a c t
Systemic Sclerosis (SSc) is an autoimmune disease of multifactorial etiology, triggered 
by a combination of genetic and environmental factors. Its varied clinical expression re-
sults from the complex physiopathogenic interaction of three main elements: prolifera-
tive vasculopathy, immune dysregulation and abnormal deposition and remodeling of 
the extracellular matrix (ECM), of which the characteristic disease fibrosis is the result. 
Early physiopathogenic events appear to be endothelial injury and imbalance in vascular 
repair with the activation of endothelial cells, the immune system and platelets, with the 
release of multiple mediators such as TH2 proinflammatory cytokines and growth factors, 
triggering a sequence of simultaneous or cascading events that involve several intracel-
lular signaling pathways. 
The most important result of these events is the hyperactivation of fibroblasts, the main 
effector cells of fibrosis, which will then produce large amounts of ECM constituents and 
secrete multiple growth factors and cytokines that perpetuate the process. In this article 
we review the main factors potentially involved in the etiology of SSc and reexamine the 
current knowledge about the most important mechanisms involved in the development of 
lesions that are characteristic of the disease. A better understanding of these physiopatho-
genic mechanisms will help identify potential therapeutic targets, which may result in 
advances in the management of this complex and debilitating disease.
© 2013 Elsevier Editora Ltda. All rights reserved.
Atualização na etiopatogênese da esclerose sistêmica
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r e s u m o
A Esclerose Sistêmica (ES) é uma doença autoimune de etiologia multifatorial, desenca-
deada pela combinação de fatores genéticos e ambientais. Sua variada expressão clínica 
resulta da complexa interação fisiopatogênica de três elementos principais: a vasculopa-
tia proliferativa, a desregulação imunológica e a deposição e remodelamento anormais da 
matriz extracelular (MEC), da qual resulta a fibrose característica da doença. Eventos fisio-
patogênicos precoces parecem ser a lesão endotelial e o desequilíbrio no reparo vascular, 
com a ativação de células endoteliais, do sistema imune e das plaquetas, com a liberação 
de múltiplos mediadores, como as citocinas proinflamatórias TH2 e os fatores de cresci-
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mento, desencadeando uma sequência de eventos simultâneos ou em cascata que envolve 
diversas vias de sinalização intracelular. O resultado mais importante desses eventos é a 
hiperativação dos fibroblastos, as principais células efetoras da fibrose, as quais passam 
a produzir grandes quantidades de constituintes da MEC e a secretar múltiplos fatores 
de crescimento e citocinas que perpetuam o processo. Neste artigo apresentamos uma 
revisão dos principais fatores potencialmente implicados na etiologia da ES e revisitamos 
os conhecimentos atuais sobre os mais importantes mecanismos envolvidos no desenvol-
vimento das lesões características da doença. O melhor entendimento desses mecanismos 
fisiopatogênicos possibilita identificar potenciais alvos terapêuticos, o que pode resultar 
em avanços no manejo dessa complexa e debilitante doença.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease of au-
toimmune origin, characterized by vascular alterations and 
progressive skin and visceral fibrosis affecting mainly the 
lungs, gastrointestinal tract, heart, and kidneys.1 The disease 
is extremely heterogeneous in its phenotypic expression, 
and its prognosis is determined by the predominant clinical 
manifestations, especially regarding visceral involvement.2-4 
Despite advances in knowledge about the mechanisms 
responsible for the disease onset, there is still a lack of un-
derstanding regarding the pathogenic process is initiated 
and undergoes intensification in each subgroup of patients, 
leading to different clinical expressions. As in other autoim-
mune diseases, especially those that are not organ specific, 
it is known that the process results from the interaction of 
multiple factors, both individual and those related to the 
surrounding environment.5 
However, the mechanisms that trigger the disease in 
genetically susceptible individuals have not yet been eluci-
dated. In this article, the main factors potentially implicated 
in the etiopathogenesis of SSc are reviewed, as well as the 
current knowledge on the most important mechanisms in-
volved in the development of SSc characteristic lesions, and 
the potential treatments directed at molecular and cell tar-
gets that have emerged from recent research are listed. 
SSc etiology: environmental factors
In the great majority of cases, SSc is considered to be idio-
pathic. However, in some situations, environmental factors 
likely play an important role in its development. These associ-
ations have been recognized for many decades, and the most 
important are those related to exposure to silica and organic 
solvents. The combined relative risk estimate (CRRE) for silica, 
calculated in a meta-analysis, was 3.20 (95% CI: 1.89-5.43) for 
men. Regarding exposure to organic solvents, the CRRE found 
in a meta-analysis was 2.91 (95% CI: 1.60-5.30),6 and, accord-
ing to another more recent meta-analysis,7 the latter is a fac-
tor associated with increased risk of SSc in men.
The possible association between silicone breast implants 
and connective tissue disorders, especially scleroderma, has 
been the subject of great controversy, generated by case re-
ports that suggested this association.8 However, a meta-anal-
ysis9 and a recent and comprehensive systematic review10 of 
the available epidemiological evidence did not confirm such 
association. 
Other environmental factors that have been implicated in 
the etiology of SSc are exposures to infectious agents, espe-
cially viruses. Among them, parvovirus B19 is an example of 
a very prevalent infection in patients with SSc.11 Regarding 
the Epstein-Barr virus, it has been demonstrated that spe-
cific adaptive immunity against the virus (the activation of 
suppressor T lymphocytes) was deficient in scleroderma pa-
tients.12 Cytomegalovirus (CMV) infects endothelial cells and 
monocytes, leading to the production of profibrotic cytokines, 
causing vascular lesions and activating fibroblasts, and may 
therefore trigger pathogenic processes associated with SSc 
development.13 
An association between positivity to anti-CMV antibodies 
and prevalence of specific autoantibodies in patients with SSc 
has been reported.14 These data suggest an association be-
tween infectious and environmental factors and the disease, 
but more studies are still necessary to determine the possible 
causal role of external agents in triggering SSc. 
SSc etiology: hormonal and genetic factors
Considering the marked predominance of SSc in women,(7:1) 
a hypothesis was raised that hormonal factors are relevant to 
the disease development. However, this has not been proven. 
For instance, an increased incidence of the disease in women 
who use oral contraceptives has not been observed.15 
Among the host factors involved in the etiopathogenesis 
of autoimmune diseases, genetic susceptibility is perhaps the 
most relevant, and therefore has been the target of extensive 
research. In SSc, as in almost all other systemic rheumatic 
diseases, polymorphisms of the main histocompatibility sys-
tem (human leukocyte antigen [HLA]) have been associated 
to the disease development, with the main associations being 
with class II HLA antigens. 
A recent study involving a fairly significant sample 
showed a positive association of haplotypes HLA-DRB1_1104, 
DQA1_0501, DQB1_0301 and, in contrast, the protective fac-
tor of haplotypes HLA-DRB1_0701, DQA1_0201, DQB1_0202, 
and DRB1_1501 in whites and Hispanics with SSc; however, in 
blacks, the association was with HLA-DRB1_0804, DQA1_0501, 
and DQB1_0301 alleles.16 Moreover, the association of the 
HLA system with autoantibody specificity in SSc has also 
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been studied. The same abovementioned study demon-
strated the association of anti-Scl70 antibodies with HLAD-
PB1_1301 antigens, of anti-centromere antibodies (ACA) with 
HLADQB1_0501 and DQB1_26, and of anti-RNA polymerase 
antibodies with HLA-DRB1_0404, DRB1_11, and DQB1_03 al-
leles(16), which illustrates the multiple infl uences that this 
gene system can exert on SSc and its clinical and immuno-
logical profi le.   
Many other genes have been implicated in SSc suscep-
tibility, mostly those encoding proteins responsible for the 
regulation and transduction of signals that comprise the au-
toimmunity and infl ammation mechanisms involved in the 
pathogenesis of SSc. One of the main associations found in 
different populations was with the gene encoding for the 
signal transducer and activator of transcription 4 (STAT4),17 
which promotes the differentiation of type-1 T helper lym-
phocytes and negatively regulates the Th2 type. 
The association of B-cell scaffold protein with ankyrin re-
peats (BANK1), which binds the B-cell receptor to intracellular 
signaling proteins such as kinases,18 and with the interferon 
regulatory factor fi ve (IRF-5), regulator of transcription of type 
I interferon genes, were also confi rmed.19 Moreover, positive 
associations have also been reported of SSc with candidate 
interleukin 23 (IL-23R) receptor genes involved in expression 
of the IL-23, a cytokine which expands the population of TH17 
lymphocytes, but SSc has only been associated with positivity 
to anti-scleroderma 70 (anti-Scl70) autoantibody, and it acts 
as a protective factor in relation to pulmonary hypertension.20 
Another gene related to SSc susceptibility is the connective 
tissue growth factor (CTGF), which induces cell proliferation, 
increasing production of ECM and chemotaxis of mesenchy-
mal cells.21    
Recently, it has been observed that interactions between 
genes are also important, such as the apparent additive ef-
fect in SSc exerted by the simultaneous presence of STAT4, 
IRF-5, and BANK1 on the susceptibility and the development 
of the diffuse clinical form and pulmonary fi brosis.17,22 Anoth-
er interesting fi nding was the sharing of genetic risk factors 
between different autoimmune diseases, exemplifi ed by the 
protein tyrosine phosphatase 22 (PTPN22) non-receptor gene, 
involved in SSc susceptibility23 as well as in diabetes mellitus 
type I,24 systemic lupus erythematous (SLE),25 and rheumatoid 
arthritis (RA).(25) Other shared genes, such as BANK1, IRF5, 
and STAT4 have also been reported as involved in SLE and RA 
susceptibility.26-28  
Another genetic factor of SSc susceptibility was recently 
demonstrated in white European populations.29 It is the mac-
rophage migration inhibitory factor (MIF)-173, a cytokine with 
immunoregulatory functions and a mediator of innate and 
adaptive immunity, which has been implicated in the patho-
genesis of vasculopathy in SSc.(30) In addition to the asso-
ciation with susceptibility, the MIF-173C allele was associated 
with the diffuse form of the disease.29 
Physiopathogenic mechanisms of systemic 
sclerosis
The current accumulated knowledge regarding the phys-
iopathogenesis of SSc derives from extensive research in 
different areas, and indicates that the pathological process 
arises from the complex interrelation between three main 
components: vascular dysfunction, innate and adaptive im-
munity dysregulation, and excess activation of fi broblasts 
and related cells, which culminates in the development of 
fi brosis (Fig. 1).31 
Proliferative vasculopathy 
The occurrence of Raynaud’s phenomenon in almost all pa-
tients with SSc, with high severity in many of them, dem-
onstrates the importance of vasculopathy in the pathogenic 
context of the disease. It is believed that the vasculopathy 
may originate after injury and activation of endothelial cells 
by unknown factors.32 The endothelial activation has been 
demonstrated in several studies that detected high plasma 
levels and increased expression of von Willebrand factor, in-
tercellular adhesion molecules, endothelin-1, and thrombo-
modulin, which also represent evidence of excessive apopto-
sis of endothelial cells.33-35 
Chronic endothelial injury results in platelet adhesion and 
activation of the fi brinolytic system, as well as in increased 
vascular permeability and leukocyte adhesion to the vascular 
wall.34 Increased levels of endothelin-1, a potent vasoconstric-
tor, have been detected in plasma and bronchoalveolar lavage 
fl uid of patients with SSc.36 This protein is responsible for in-
creasing leukocyte adhesion to the endothelium, promoting 
migration and proliferation of smooth muscle cells into the 
intima layer of vessels and activating fi broblasts. 
This process promotes the synthesis and deposition of 
ECM molecules, leading to fi brosis with loss of elasticity and 
progressive reduction of the vascular lumen, causing progres-
sive tissue necrosis and hypoxia.37 
Tissue hypoxia promotes angiogenesis (formation of new 
vessels from remaining functional vessels) and vasculogen-
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Fig. 1 – Physiopathogenic mechanisms of systemic sclerosis: 
the interaction between vasculopathic, infl ammatory, and 
autoimmune factors lead to hyperactivation of effector cells 
and production of tissue fi brosis.
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esis (formation of new vessels from endothelial progenitor 
cells),38 in order to restore cell oxygen supply. Due to multi-
ple causes not yet understood, these processes are deficient 
in SSc, and there is an imbalance between angiogenic and 
angiostatic factors and ineffective vascular repair.39-40 
The result is the formation of morphologically aberrant 
and dysfunctional capillaries, which can be viewed in the 
nailfold capillaroscopy examination. It is now known that 
tissue hypoxia present in SSc plays an important patho-
genic role in the disease through different factors, such as 
the production of hypoxia-induced factor (HIF-1), whose 
production and deficient regulation is ineffective in restor-
ing normal blood pressure levels of oxygen. This deficiency 
creates a vicious circle, with increased activation of immune 
cells, increased activation of fibroblasts, increased levels of 
transforming growth factor β (TGFβ), and ECM deposition, 
which in turn aggravate the hypoxic environment. Further-
more, the increase in oxidative stress caused by hypoxia has 
a proinflammatory and profibrotic effect, exerted by reactive 
oxygen species (ROS).41
An additional factor that contributes to microvasculopa-
thy in SSc is the pericytes, cells very close to the endothe-
lium that normally inhibit cell migration and vascular pro-
liferation. These cells are hyperplastic and hyperactivated in 
SSc, inhibiting the process of angiogenesis and transdiffer-
entiating into myofibroblasts, producing excess ECM, which 
accumulates in the perivascular area and aggravates the 
proliferative vasculopathy of the disease.38 Table 1 summa-
rizes the most relevant physiopathological events in relation 
to SSc vasculopathy.
Autoimmunity and inflammation
Another important factor implicated in the pathogenesis 
of SSc is the involvement of both humoral and cellular im-
mune system, whose mediators are the connection between 
vascular disease and tissue fibrosis, as they are involved in 
both processes.32 The involvement of the humoral immune 
system is demonstrated by the presence of B lymphocyte 
infiltrates with expression of chronic activation markers 
(CD19, CD85), which have been detected in patients with 
SSc skin using DNA microarray techniques.42 The homeo-
stasis of circulating B lymphocytes is altered, expanding 
the population of non-activated cells (naïve) and reduc-
ing the number, but increasing the activation of memory 
B cells.43 This knowledge has led to the use of therapies di-
rected against B cells (monoclonal antibodies belimumab 
and rituximab) in the treatment of patients with SSc, as 
well as to the blocking of the costimulation between the 
latter and T lymphocytes.44 
The specific autoantibodies, which represent one of the 
attributes of the disease, characterize its clinical forms and 
have important prognostic associations; they are the most 
obvious expression of the humoral immune system involve-
ment in the etiopathogenesis of SSc. The main autoanti-
bodies whose pathogenic potential has been established, 
in addition Scl70 and ACA, are those directed against endo-
thelial cells and against the platelet-derived growth factor 
(PDGF) receptor.32
ACA are characteristic of limited SSc, which is gener-
ally more benign than the diffuse form, but is associated 
with later development of pulmonary hypertension, one 
of the most severe complications of the disease, as well as 
digital ulcers and important gastrointestinal involvement. 
Patients with limited SSc may have anti-Th/To antibod-
ies (more frequent in men, with interstitial pulmonary in-
volvement and earlier mortality),45 anti-PM/Scl antibodies 
(associated with myositis, calcinosis, acro-osteolysis and 
interstitial lung disease),46 and the anti-U1RNP antibodies 
(that characterize overlapping forms between SSc, SLE, and 
myositis).47  
Conversely, the presence of anti-Scl-70 is associated with 
the diffuse form of SSc, with interstitial pulmonary involve-
ment and increased risk of renal crisis, especially in the 
early years of the disease. Musculoskeletal complications, 
such as flexion contractures of the fingers, are common and 
very disabling.47 More rarely, the anti-RNA polymerase III 
(POL3) antibodies occur in the diffuse form, whose patients 
have a high frequency of renal crisis, rapidly progressive 
skin fibrosis, and little pulmonary and gastrointestinal in-
volvement.48 The diffuse form can also show the presence 
of anti-U3RNP (fibrillarin), which is more common in black 
individuals and has worse prognosis, with severe pulmo-
nary fibrosis, arterial pulmonary hypertension, pigmenta-
tion alterations, and joint contractures.49
The pathogenic role of cell immunity, represented main-
ly by T lymphocytes, is evidenced in SSc by the increase in 
endothelial transmigration of T CD4 + cells originating from 
perivascular inflammatory infiltrates and oligoclonal acti-
vation of these cells, resulting in profibrotic cytokine pro-
duction.50 The oligoclonal activation of T-lymphocytes was 
demonstrated by the increased levels of soluble IL-2 recep-
tor in the serum of SSc patients, which showed a strong 
association with skin involvement (Rodnan skin score) in 
the disease.51 
The predominant production of these cytokines (IL-4, 
IL-5, IL-6, IL-10, IL-13, and monocyte chemoattractant pro-
tein-1 [MCP-1]) results from an imbalance between the pro-
files of T helper type 1 (TH1) and type 2 (TH2) cells, derived 
from TH2- cells, which is the predominant profile in SSc 
Table 1 – Physiopathogenesis of vasculopathy in 
systemic sclerosis.
Effector cells Physiopathogenic 
processes 
Molecules 
involved 
Endothelial cells
Smooth muscle 
cells of vessels
Pericytes
r-FTJPOBOEBQPQUPTJTPG
endothelial cells 
r0YJEBUJWFTUSFTT
r*ODSFBTFEWBTDVMBS
permeability 
r1MBUFMFUBDUJWBUJPOBOE
thrombosis
r4USVDUVSBMWBTDVMPQBUIZ
(progressive reduction of 
vascular caliber due to 
hypertrophy and fibrosis) 
Impaired 
neovascularization
r7PO8JMMFCSBOE
factor
r)*'
r&OEPUIFMJO
r7$".
r&-".
r7&('
r3FBDUJWFPYZHFO
species
r$ZUPLJOFT
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and promotes worsening of tissue fibrosis.52 Current knowl-
edge allows for the inference that the processes triggered 
by profibrotic cytokines derived from the interaction be-
tween T lymphocytes and fibroblasts play a key role in the 
development of fibrosis (Table 2).
Development of fibrosis: fibroblast activation
The third key pathogenic mechanism involved in SSc, and 
the most representative of the disease, is fibrosis, which 
lends its name to the disease and affects the skin, lungs, 
heart, digestive tract, kidneys, and musculoskeletal system. 
The extent of skin fibrosis is associated with mortality by 
SSc, as recently demonstrated both in the European and 
Brazilian populations.3-4 
Fibrosis results from complex interactions between mul-
tiple concurrent or cascading processes, in which dozens of 
cell mediators, cytokines and their receptors, chemokines, 
growth factors, and intracellular signaling molecules are 
present (Table 3). The result of this interaction is the ex-
cessive production and accumulation of insoluble material 
in the tissues that constitutes the ECM. Fibrillar collagens 
types I and II, type VII collagen, and elastin and fibrillin fi-
brils are mainly found in ECM, as well as enzymes that pro-
mote the production of collagen crosslinks.53 
Regarding fibrosis cell mediators, the fibroblast is the 
cell primarily responsible for the production and remodel-
ing of the ECM, and its main physiological importance lies 
in the healing process of connective tissue injuries, having 
a self-limited action, depending on the injury extent.53 In 
SSc, as in other fibroproliferative diseases, there is a state 
in which the fibroblast is permanently hyperactivated, with 
altered expression of genes that determine ECM overpro-
duction. 
In SSc, one of the mechanisms responsible for this hy-
peractivation is the mechanotransduction abnormality, 
in which fibroblasts and myofibroblasts would be able to 
perceive tensional forces and change their intracellular 
signaling in response, leading to altered homeostasis and 
remodeling of the ECM.54 In addition to the fibroblasts, myo-
fibroblasts also participate in the process of fibrosis forma-
tion in SSc. These contractile and ECM-producing cells orig-
inate from the transdifferentiation of fibroblasts, epithelial 
cells, and pericytes.55 Unlike the normal healing process, in 
which myofibroblasts occur only transiently in granulation 
tissue, in SSc these cells become permanent, producing ar-
eas of fibrosis with contracture of the ECM.56 
The bone marrow also contributes to the increase of the 
amount of profibrotic cells, with the release of pluripotent 
mesenchymal cells and fibroblast progenitors (fibrocytes). 
The latter physiologically replenish the population of fibro-
blasts maintaining tissue homeostasis, but they also exert 
a pathogenic role in SSc. Fibrocyte precursors migrate and 
accumulate in tissues by gradient of chemokine receptors 
(CRs), such as CCR3, CCR5, and CXCR4.32 These receptors 
and their ligands have been found at high levels in the skin 
of patients with SSc.57 Furthermore, tissue-infiltrating fi-
brocytes have also been implicated in the pathogenesis of 
pulmonary fibrosis disease.58 
The main effector proteins involved in the fibrosis mech-
anisms in SSc are the cytokines, chemokines, and the fam-
ily of ECM growth factors, which induce fibrogenic cell re-
sponse by increasing the expression of genes encoding ECM 
constituents.59 Profibrotic cytokines play a pathogenic role 
in SSc. The best-known and most often studied cytokine re-
garding its mechanisms in fibrosis is IL-4, which stimulates 
the synthesis of TGFβ and CTGF; it also promotes the migra-
tion, proliferation, and synthesis of collagen by fibroblasts. 
High levels of IL-4 were found in serum and tissues of pa-
tients with SSc, and a larger number of T cells that produce 
this cytokine were detected in these patients.60-61 It is also 
known that IL-13 induces the expression of type I collagen 
gene and that its levels are elevated in patients with SSc, 
but its possible role in the induction of fibrosis is not well 
established.60 Very recently, a study found increased levels 
of IL-6 in serum and tissues of patients with diffuse SSc, 
which was associated with more severe skin involvement 
and increased mortality after three years,62 suggesting that 
IL-6 antagonism would be a promising therapeutic target in 
this situation.
Perhaps the most important of all effector proteins of fi-
brosis is TGFβ, considered to be the orchestrator of the phys-
Table 2 – Autoimmunity and inflammation in the 
pathogenesis of systemic sclerosis.
Effector  
cells
Physiopathogenic 
processes
Molecules 
involved
T Lymphocytes 
B Lymphocytes
r(FOFSBMBOEMPDBMBDUJWBUJPO
of T and B lymphocytes, 
oligoclonal expansion
r5SBOTFOEPUIFMJBMNJHSBUJPO
of CD4+ activated T 
lymphocytes
r1SPEVDUJPOBOESFMFBTFPG
pro-fibrotic autoantibodies 
and cytokines
r"VUPBOUJCPEJFT
(anti-PDGF, anti-
endothelial cells, 
anti-Scl70, anti-
centromere)
r1SPàCSPUJD
cytokines: IL-4, 
IL-6, IL-10, IL-13
r*-SFDFQUPS
Table 3 – Physiopathogenesis of fibrosis in systemic 
sclerosis.
Effector cells Physiopathogenic 
processes
Molecules 
involved
Fibroblasts
Myofibroblasts
Pericytes
Smooth muscle 
cells of vessels 
Fibrocytes (bone 
marrow)
r%JGGFSFOUJBUJPOBOE
trans-differentiation 
of fibroblasts
r&YDFTTJWFTZOUIFTJTPG
ECM (mainly collagen 
fibers)
r5JTTVFSFNPEFMJOH
r3FEVDUJPOJO&$.
resorption 
r(SPXUIGBDUPST
(TGFβ and 
TGFβRII, CTGF, 
PDGF, EGR-1)
r$IFNPLJOFT	$3T
MCP-1)
r*OUSBDFMMVMBS
signaling 
molecules 
(SMADs, tyrosine-
kinases, MAPK-, 
GNK-, BMPs, EGR-
1, Wnt-β-catenin
r/VDMFBSIPSNPOF
receptors (PPAR-ࢢ)
r&OEPUIFMJO
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iological process of tissue repair and known to be involved 
in the development of pathological fibrosis, as in SSc.59 TGFβ 
is produced by fibroblasts, T cells, monocytes, and platelets, 
and it is released as a latent complex that is activated by tis-
sue injury to its biologically active form within the ECM, ex-
erting its function by binding to a specific receptor (TGFβRII) 
on the surface of different cell types.37
After this binding, an intracellular signaling cascade 
starts, which results in the expression of target genes such as 
type I collagen, CTGF, and plasminogen activator inhibitor-1, 
among others.63 The main control of TGFβ intracellular sig-
naling system is exercised by the SMAD system (SMAD2 and 
SMAD3 activators, as well as endogenous inhibitor SMAD7 
and its cofactors), whose dysregulation results in increased 
fibrogenesis, a phenomenon already demonstrated in SSc.64 
Recently, other regulatory mechanisms of TGFβ were studied 
and their importance was demonstrated in the pathogenesis 
of SSc, such as c-Abl kinase (c-Abelson, a tyrosine kinase im-
plicated in the pathogenesis of chronic myeloid leukemia), 
a potent regulator of the TGFβ-induced profibrotic response 
in fibroblasts.65 
Imatinib, an inhibitor of c-Abl, reduces fibrotic responses 
in animal models and have shown to be promising in the 
treatment of patients with SSc.44,66 Also relevant as me-
diators of profibrotic cell response to TGFβ are genes from 
the early growth response (EGR) family, particularly EGR-1, 
whose expression is induced by chemical or mechanical 
tissue injury and whose levels are elevated in skin lesions 
of SSc, as demonstrated in a murine model of bleomycin-
induced scleroderma.67
Another relevant mechanism in the process of fibrosis 
that has recently been demonstrated, but whose role still re-
quires elucidation, is the Wnt-β-catenin, an important intra-
cellular signaling pathway in the embryonic period during 
organogenesis whose posterior and aberrant reactivation is 
associated with disease (cancer, for instance) by increasing 
fibroblast activity and promoting transdifferentiation. In bi-
opsies of scleroderma patients, this pathway was activated 
and found responsible for significant production of fibrosis 
and lipoatrophy.68 
In addition to TGFβ, other growth factors are important 
in the pathogenesis of SSc, such as CTGF, whose effects are 
similar to those of TGFβ and whose levels are increased in 
lesions of patients with SSc. Its expression is stimulated by 
TGFβ itself, by hypoxia, and by ET-1.37 PDGF is produced by 
fibroblasts, platelets, macrophages, and endothelial cells, 
with important mitogen and chemoattractant activity for fi-
broblasts, inducing their production of collagen, fibronectin, 
and proteoglycans, and the release of profibrotic mediators 
IL-6 and MCP-1. This is another growth factor implicated in 
the interaction with TGFβ and CTGF, which was detected at 
high levels in the lungs of patients with SSc.69 
In addition to all the aforementioned mechanisms, which 
help to promote excessive fibrogenesis, in SSc there are also 
abnormalities in the physiological counterregulation sys-
tems that normally prevent the occurrence of fibrosis. This 
was demonstrated in the case of SMAD7, signaling mole-
cules that exert an antifibrotic role through negative regula-
tion of TGFβ action.64
Searching for antifibrotic mechanisms that could be ex-
plored for therapeutic purposes in SSc, the peroxisome pro-
liferator activated receptor-gamma (PPAR-ࢢ) was identified. 
This molecule is a key hormonal nuclear receptor in lipid 
and glucose metabolism, which has been increasingly asso-
ciated with ECM remodeling and fibrosis, capable of modu-
lating TGFβ signaling and mesenchymal cell plasticity. It was 
found that this receptor is involved in an important anti-
fibrotic mechanism, and its expression and activity were 
found to be reduced in patients with SSc.70 Natural or syn-
thetic PPAR-ࢢ agonists, such as the antidiabetic drugs piogli-
tazone or rosiglitazone, or tissue stimulation of its expres-
sion could, therefore, play a role in the treatment of fibrosis. 
Table 3 summarizes the elements involved in the physio-
pathological process of establishment fibrosis in SSc. 
In spite of the fact that SSc is considered to be incurable, 
in recent years intensive research has led to the identifica-
tion of antifibrotic cellular and molecular targets and the 
development of therapeutic options directed against them. 
Table 4 lists some treatments aimed at targets (mostly dis-
cussed above) that have emerged from in vitro studies, ani-
mal models, and early trials in humans.44 A better under-
standing of the physiopathological mechanisms of SSc has 
shed light on the factors that most likely initiate the process 
and lead to its perpetuation. 
Considering that the vascular lesion and its defective re-
pair are known early events, it is possible that the clinical 
expression of the disease depends more on the magnitude 
of vascular changes and its chronicity than on the trigger-
ing event itself.41 Therefore, efforts are needed in order to 
diagnose the early establishment of vasculopathy and to 
institute treatment in order to halt the progression of the 
process. In addition, the elucidation of the molecular mech-
anisms involved in SSc may contribute to the identification 
of other potential targets to be assessed in the search for 
more specific and effective treatments for this severe and 
debilitating disease. 
Table 4 – Therapies directed against targets in systemic 
sclerosis.
Therapeutic target Drugs (available or in development)
r*OUSBDFMMVMBS.PMFDVMFT
PPARࢢ, Notch Rosiglitazone, inhibitors of the Notch 
signaling pathway
r$ZUPLJOFTHSPXUIGBDUPSTDIFNPLJOFTJOUSBDFMMVMBSTJHOBMJOH
pathways
MCP-1/CCR2 CCR2 inhibitors (PF-04136309, BMS-
741672, MLN1202)
TGFβ, CTGF, IL-13, IL-6 Monoclonal antibodies (CAT-192, 
FG3019, QAX576, tocilizumab)
Chemokines (CXCL12, 
CCL4)
CXCR4, CCR2 inhibitors
Wnt signaling pathway PRI-724 inhibitors, resveratrol
r#MPDLJOHPGUIFDPBHVMBUJPOTZTUFNBDUJWBUJPO
Thrombin Inhibitor: dabigatran
r5IFSBQJFTEJSFDUFEBHBJOTU5BOE#DFMMT
T/B co-stimulation Abatacept (CTLA4-Ig)
CD20, BAFF (BlyS) Monoclonal antibody (rituximab, 
belimumab)
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